10 Years Of MedImmune: What Trademark Owners Learned

Law360, New York (February 14, 2017, 11:09 AM EST) -- Last month marked 10 years since the U.S. Supreme Court sided with MedImmune in a royalty dispute with Genentech, transferring the power within a license agreement from the licensor to the licensee. This Law360 Expert Analysis series explores the decision's impact on licensing and litigation.

James E. Griffith

Michelle Bolos Ten years ago, the Supreme Court redefined the standards for declaratory judgment jurisdiction in patent cases, forcing practitioners to reimagine intellectual property enforcement strategies. In MedImmune LLC v. Genentech Inc., the Supreme Court held that a...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.